Patients with SPC (p < 0.001; OR: 0.302; 95% CI: 0.157-0.584) and patients with methylation of the MGMT promoter region (p = 0.005; OR: 0.375; 95% CI: 0.190-0.739) were less likely to receive a tumor-specific therapy in the 30 days prior to death. Here, MGMT is linked to neoplasm.